Classical ataxia telangiectasia (A-T) is an early-onset progressive neurodegenerative disorder caused by loss of function of the ATM gene. Affected individuals are unable to walk a few steps independently by early adulthood. This phenotype is most frequently caused by biallelic null mutations in ATM that result in the absence of ATM, a large 370 kDa protein kinase (Taylor and Byrd, 2005) . ATM phosphorylates many target proteins such as H2AX, MDC1, 53BP1, Nbs1, BRCA1, Chk2 and p53 that function to regulate DNA DSB repair, chromatin remodelling, cell cycle checkpoint activation, gene transcription, protein translation and apoptosis (Lavin, 2008) . In A-T, in the absence of ATM there is a defective response to both intrinsically and extrinsically derived cellular damage. In the brain, damaged cells may become incorporated into neuronal tissues, leading to neurodegeneration, possibly as a result of failure of apoptosis (Shull et al, 2009) .
Clinically, A-T is quite heterogeneous with some nonclassical patients showing a much milder clinical progress as a consequence of retaining expression of either some normal (McConville et al, 1996; Sutton et al, 2004) or mutant ATM protein (Stankovic et al, 1998; Carrillo et al, 2009; Verhagen et al, 2009 ) with residual ATM kinase activity. Indeed, some A-T patients are not diagnosed until adulthood (Sutton et al, 2004; Hiel et al, 2006) .
Separate studies of A-T families (Olsen et al, 2001; Thompson et al, 2005b) and of breast cancer families (Renwick et al, 2006) have shown that carrying a single ATM mutation doubles the risk of breast cancer. The presence of the missense mutation, c.7271T4G (p.Val2424Gly), further increases the risk (Stankovic et al, 1998; Bernstein et al, 2006) . Also, A-T patients are at a considerable increased risk of developing breast cancer; 45% by the age of 50 years (Reiman et al, 2011) compared with B9% in heterozygous carriers.
We report the occurrence of a mild form of A-T, with biallelic ATM mutations in a 44-year-old breast cancer patient (A-T213) who was investigated following a severe early and late reaction to radiotherapy.
MATERIALS AND METHODS

Ethical approval
Ethical Approval was given by the National Research Ethics Committee (REC Reference 07/H1210/155) and patient A-T213 gave informed consent.
Cell culture
Epstein -Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) were established from A-T patient and control lymphocytes. These LCLs were cultured in RPMI-1640 medium (Sigma-Aldrich, Irvine, UK) supplemented with 10% fetal calf serum (FCS; PAA Laboratories, Pasching, Austria). For transfected LCLs, 200 mg ml -1 of hygromycin B (Invitrogen, Paisley, UK) was added to the media.
Colony-forming assays
Serial dilutions of TERT-immortalised fibroblasts were irradiated with 1 to 5 Gy of g-rays and seeded on to a lethally irradiated (35 Gy) feeder layer of normal fibroblasts (6 Â 10 4 cells per 9.0 cm dish) in DMEM (Sigma-Aldrich) with 10% FCS. Cells were plated in quadruplicate and incubated in 5% CO 2 at 37 1C for 18 -21 days with medium changing. The medium was removed, colonies fixed with formaldehyde and stained with 0.5% Methylene Blue (Fisher Scientific, Loughborough, UK). The number of colonies on each plate was counted and percentage survival calculated.
Modelling ATM mutations
The ATM cDNA (mRNA RefSeq NM_000051.3) representing the complete open reading frame and coding sequence was cloned into plasmid pcDNA4/HisMax (Invitrogen) to create pcDNA4/HisMax-ATM. This was used as a template in subsequent mutagenesis and cloning reactions. Site-directed mutagenesis was achieved using the Quikchange II site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands). Both the 1A4G and the 8672G4A ATM mutants were sequenced in full to verify the presence of the desired sequence change and absence of any unwanted mutation(s) acquired during the mutagenesis step. Full-length mutated ATM constructs were transfected into ATM-null lymphoblastoid cells (Barone et al, 2009) . For detailed methods, see Supplementary Information (Stewart et al, 2001) .
Immunoblotting for ATM expression and ATM kinase activity
To analyse ATM activity, cells were either mock irradiated or exposed to 5 Gy ionising radiation and harvested after 30 min, and nonirradiated cells were used for ATM expression analysis. Cell pellets were resuspended in UTB buffer (9 M urea, 50 mM Tris, pH 7.5, 150 mM b-mercaptoethanol) and lysed on ice by sonication. Lysate (50 mg) was separated by SDS -polyacrylamide gel electrophoresis and the proteins transferred to nitrocellulose membrane (Pierce, Rockford, IL, USA). Nitrocellulose strips were subjected to immunoblotting and protein bands visualised using the enhanced chemiluminescence (ECL) system (Amersham, Little Chalfont, UK) and exposure to Hyperfilm MP autoradiography film (GE Healthcare, Little Chalfont, UK). Antibodies used for immunoblotting were ATM 11G12 (custom-made mouse monoclonal), pATM Ser1981 #AF1655 (R&D Systems, Abingdon, UK), Smc1 #A300-055A, pSmc1 Ser966 #A300-050A, KAP-1 #A300-275A, pKAP-1 Ser824 #A300-767A (Bethyl Laboratories, Universal Biologicals, Cambridge, UK), Nbs1 #Ab398, pNbs1 Ser343 #Ab47272 (Abcam, Cambridge, UK), pP53 Ser15 #9284, pChk2 Thr68 #2661, CREB #48H2 (Cell Signaling Technology, NEB, Hitchin, UK), pCREB Ser121 #NB100-410 (Novus Biologicals, Cambridge, UK), g-H2AX (Millipore, Watford, UK), H2A (Millipore), BRCA1 Ser1423 (Bethyl Laboratories), BRCA1 (Merck, Nottingham, UK) and Chk2 (gift from Dr G Stewart).
In vitro ATM kinase assay
Patient-derived LCLs were either mock irradiated or exposed to 5 Gy 137 Cs g-rays and incubated for 30 min at 37 1C. Cells were harvested and lysed on ice for 30 min in TGN lysis buffer (50 mM Tris, pH 7.5, 150 mM sodium chloride, 10% glycerol, 50 mM b-glycerophosphate, 1% Tween-20, 0.2% nonidet P40 alternative, 1 mM dithiothreitol, 0.1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 mg ml -1 aprotinin, 5 mg ml -1 leupeptin hydrochloride and 2 mg ml -1 pepstatin A). The ATM kinase was immunoprecipitated from 1 mg of each whole-cell lysate using 10mg anti-ATM antiserum (Ab-3, Merck Chemicals, Darmstadt, Germany) for 2 h at 4 1C. The ATM immunoprecipitates were pulled down using 30 ml of Protein A agarose beads (Sigma-Aldrich) for 2 h at 4 1C. Bead complexes were washed twice in TGN buffer, once in TGN buffer plus 0.5 M lithium chloride and twice in ATM kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl 2 , 10mM MnCl 2 , 50mM b-glycerophosphate, 1 mM dithiothreitol, 0.1 mM sodium orthovanadate, 1 mM sodium fluoride, 0.1 M 4-(2-aminoethyl) benzenesulfonyl fluoride, 10 mg ml -1 aprotinin, 5 mg ml -1 leupeptin hydrochloride and 2 mg ml -1 pepstatin A) to remove residual detergent.
Each immunoprecipitate was resuspended in kinase buffer supplemented with 20 mM ATP (Sigma-Aldrich), 5 mg of purified GST-p53 1À72 substrate and 10 mCi 32 P[g-ATP] (New England Nuclear, Boston MA, USA) and incubated at 30 1C for 6 min. Reactions were terminated by the addition of SDS sample buffer (250 mM Tris, pH 6.8, 8% (w/v) sodium dodecylsulphate, 10% (v/v) glycerol, 0.01% (w/v) bromophenol blue, 400 mM dithiothreitol), incubated at 100 1C for 5 min and proteins were fractionated on 6%/8% biphasic SDS -polyacrylamide gels. The lower gel phase was dried at 80 1C for 1 h and exposed to autoradiographic film to visualise phosphorylation of the GST-p53 1À72 substrate. The protein in the upper gel phase was transferred to nitrocellulose membrane (Pierce) and immunoblotted for the presence of immunoprecipitated ATM protein using anti-ATM antiserum (custom-made mouse monoclonal 11G12). Proteins were visualised as above.
RESULTS
Clinical and neurological features
Patient A-T213, a 44-year-old working mother, developed a lump in her right breast and was diagnosed with breast cancer (T2 G2, two nodes positive, ER-positive carcinoma of right breast). Treatment consisted of a lumpectomy followed by adjuvant chemotherapy (FEC) and radiotherapy (standard protocol delivering 40 Gy in fifteen fractions over 3 weeks). Post treatment, an acute radiation reaction at the severe end of the normal spectrum developed, followed by a late reaction manifest as shrinkage and deformation of the breast (Figure 1 ). The patient was investigated because of severe reaction to radiotherapy. Diagnostic testing of BRCA1 and BRCA2 genes by unidirectional DNA sequencing and MLPA did not detect any mutations.
Patient A-T213 walked into the clinic unaided and unsupported. There was no ataxia and tandem gait, feeding and swallowing were normal. There was no oculomotor apraxia, no hypometric saccades, no pursuit abnormalities and end gaze-evoked nystagmus but there was mild right esotropia. The patient showed no adventitious movements. Finger -nose coordination showed some end dysmetria and there was diminished vibration sense and joint position sense up to knees, confirmed by EMG (mild axonal polyneuropathy) and absent ankle and knee reflexes bilaterally.
Cellular radiosensitivity
Cultured skin fibroblasts from patient A-T213 showed increased radiosensitivity by colony-forming assay, but were not as sensitive as cells from a classical A-T patient (Figure 2) . Similarly, examination of chromosomal radiosensitivity of blood from patient A-T213 showed a similar level of IR-induced damage that was B3 Â more than the control, but less than 'classical' A-T patients (A-T1 and A-T2, Table 1 ). Finally, following exposure to IR, the patient's fibroblasts showed a similar number of ATMdependent MDC1, gH2AX, 53BP1 and BRCA1 foci to the normal control, although they were noticeably less bright (Supplementary Figure 1 ). All these end points indicate some retained ATM function in cells from patient A-T213.
ATM mutation analysis
Two ATM mutations, c.8672G4A. (p.Gly2891Asp) and c.1A4G (Figure 3 ), were identified in the cells from patient A-T213 by DNA sequencing the exons and exon/intron boundaries of the ATM gene. Alterations were confirmed by sequencing cDNA derived from the LCLs of patient A-T213. Sequencing of the parental ATM genes confirmed that one mutation was carried on each allele of chromosome 11, the c.8672G4A mutation was paternal and the c.1A4G mutation maternal in origin.
The mutations are located in unusual positions, and both could theoretically result in expression of mutant ATM protein. The c.1A4G affects the first base in the coding sequence and might be expected to ablate the initiation of ATM protein translation altogether. However, mutation of the initiation codon AUG to GUG could potentially result in the expression of ATM protein if the GUG in the RNA was able to allow translation. The c.8672G4A (p.Gly2891Asp) is a missense mutation located in the first base of exon 60 (NM_000051.3) in the kinase domain. It was expected that at the cDNA level the c.8672G4A mutation might result in loss of exon 60. However, this was not the case and, therefore, this mutation could also potentially result in the expression of mutant ATM protein. Expression of mutant ATM protein with some residual kinase activity from either one or both mutations could contribute to the milder clinical and cellular phenotype of patient A-T213.
Cellular ATM protein expression and kinase activity
The LCL of patient A-T213 expressed ATM protein, although the level was reduced compared with a normal LCL (Figure 4 ). Both A-T213 LCL ( Figure 4A ) and skin fibroblast lysates ( Figure 4B and C) showed residual ATM kinase activity. Therefore, both kinase assays in vivo confirmed the presence of ATM with kinase activity in the patient's cells. In order to estimate the level of ATM kinase activity, we performed an in vitro ATM kinase assay. The ATM protein immunoprecipitated from A-T213 LCL lysate showed greatly reduced activity towards a p53 substrate after DNA damage (B12% of normal) ( Figure 5A and B).
Finally, using LCL lysates we compared the ATM kinase activities of cells derived from patient A-T213 with cells from another breast cancer patient who was diagnosed with A-T following a severe reaction to radiotherapy (A-T109, c.7271T4G homozygous) (Stankovic et al, 1998) . Although the level of ATM expression was highest in the c.7271T4G cells, the level of kinase activity appeared to be slightly greater in cells from patient A-T213 (Supplementary Figure 2) .
Size and activity of the mutant ATM proteins
Immunoprecipitation of ATM from an LCL derived from patient A-T86, carrying the initiating codon mutation, c.2T4C, on one allele and a null mutation on the second allele, revealed an ATM protein expressed at a lower level and slightly lower molecular weight ( 3 and 4) shows the presence of some ATM kinase activity towards the ATM targets Smc1, KAP1, Nbs1 and CREB after exposure to IR, but this is reduced compared with lysate from a normal LCL (lanes 1 and 2) . LCL lysate from a classical A-T patient A-T236, which does not express ATM, is shown in lanes 5 and 6. (B and C) Time course of phosphorylation of different ATM downstream targets by A-T213 fibroblast ATM protein, showing the presence of kinase activity at 1 h compared with the classical A-T patient (A-T248) but reduced activity compared with normal ATM (normal 2).
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Exon 60 with the presence of the c.1A4G mutation was not detected, probably because it was obscured by the full-length ATM from the c.8672G4A (p.Gly2891Asp) allele ( Figure 5 , compare lanes 5 and 6 and lanes 7 and 8). Consistent with this assertion was the finding that the ATM protein expressed from the c.2T4C mutant allele in the LCL from patient A-T187 could not be discriminated from protein expressed from the second allele that was essentially fulllength p.Arg3047X (c.9139C4T) ( Figure 5 , lanes 9 and 10). Interestingly, the level of ATM kinase activity in A-T213 was clearly greater than that of ATM immunoprecipitated from A-T cells carrying the mutation c.2T4C, which did not demonstrate any in vitro kinase activity ( Figure 5A and B) . This suggests that the ATM kinase activity in cells of patient A-T213 is from the c.8672G4A (p.Gly2891Asp) allele.
In order to determine whether one or both mutant alleles expressed ATM with some kinase activity, each mutation was modelled separately by site-directed mutagenesis of full-length normal ATM cDNA. Both the mutant protein associated with the c.1A4G and the p.Gly2891Asp mutant protein are shown in Figure 6A . Interestingly, the c.1A4G protein was of lower molecular weight than wt ATM consistent with the use of a downstream methionine for initiation. In contrast to the level of ATM present in a normal LCL, the levels of both mutant proteins were low, although expression of the p.Gly2891Asp mutant protein was significantly higher than the c.1A4G protein ( Figure 6A , lanes 4 and 5). We were unable to measure the level of ATM kinase activity in either mutant protein because the levels of expression were too low. However, it was possible to analyse ATM kinase activity in the higher level of p.Gly2891Asp produced when it was expressed with N-terminal tags ( Figure 6B ). The p.Gly2891Asp mutant protein was autophosphorylated on ser1981 and was able to phosphorylate the ATM targets Smc1, KAP1, Nbs1 and CREB ( Figure 6C , lane 6) after exposure to IR. The level of phosphorylation was greater than in cells with vector alone ( Figure 6C , lane 4) but substantially lower than in cells with ATM wt ( Figure 6C, lanes  2 and 8) . Therefore, of the two possible expressed mutant ATM proteins in A-T213, there was clear evidence that the p.Gly2891Asp mutant protein was active. Consequently, the ATM kinase activity in the cells of patient A-T213 was unlikely to be due to protein expressed from the c.1A4G mutation. Indeed, the mutant c.1A4G ATM cloned into pMEP4 was expressed as a lower molecular weight protein consistent with the kinase-inactive truncated protein expressed from the c.2T4C ATM mutant.
DISCUSSION
At the time of breast cancer diagnosis and until the end of treatment, there was no clinical reason to suspect a diagnosis of A-T in patient A-T213. Had it not been for the severe reaction to radiotherapy, it is possible that the disorder would have remained unrecognised as neurological features were minor. The A-T, therefore, was very mild. However, fresh lymphocytes, an LCL and (lanes 1 and 2) , absence of ATM in an LCL from a classical A-T patient (A-T183, lanes 3 and 4) and reduced expression of ATM in LCL from A-T213 (lanes 5 and 6). Whereas the ATM in patient A-T213 appears to be full length, the ATM in an LCL from patient A-T86 with the c.2T4C mutation (and also null mutation c.7665delinsGTGA;p.His2555Gln ins*) is slightly truncated (lanes 7 and 8). It is likely that truncated ATM from c.2T4C in patient AT187 is obscured by the p.Arg3047X (c.9139C4T) mutant protein (lanes 9 and 10) and the truncated ATM from c.1A4G in patient A-T213 is obscured by the p.Gly2891Asp (c.8672G4A) mutant protein (lanes 5 and 6). 1 and 7) . The p.Gly2891Asp (8672G4A) protein autophosphorylated Ser1981 following IR (lane 6) to levels comparable to that of ATM wt protein (lanes 2 and 8). Levels of IR-induced phosphorylation of ATM targets Smc1, KAP-1 and Nbs1 by the p.Gly2891Asp (8672G4A) protein were substantially lower than those for the ATM wt protein (lanes 2 and 8) but higher than for vector alone.
fibroblasts from the patient all showed a clearcut increased radiosensitivity and defective focus formation of damage response proteins, although not to the same extent as cells from a classical A-T patient. In the context of this mild presentation, the two ATM mutations, c.8672G4A (p.Gly2891Asp) and c.1A4G, in patient A-T213 are both of considerable interest.
Interestingly, the c.8672G4A missense mutation was reported in one of the breast cancer cases (but not in the controls) in the study of Renwick et al (2006) . Our study of this sequence change now confirms this as a true ATM mutation, allowing a low level of ATM expression with greatly reduced ATM kinase activity.
The ATM protein derived from the allele carrying the c.1A4G mutation affecting the initiating methionine was truncated in the same way as a protein derived from another mutation (c.2T4C) in the same codon. Cells from a patient with the c.2T4C and an ATM-null mutation expressed a truncated ATM protein with no measurable ATM kinase activity. Therefore, it is unlikely that the c.1A4G derived protein has any activity. In both cases, it is possible that translation of transcripts may initiate at the second or third in-frame AUG codons at codons 94 or 125, producing an N-terminally truncated ATM protein. The smaller molecular weight of ATM immunoprecipitated from both the c.2T4C mutant cells and the modelled c.1A4G is consistent with this.
An alternative hypothesis is that initiation occurs at a downstream out-of-frame AUG and that the truncated ATM protein expressed from the c.1A4G and c.2T4C mutant alleles is the result of uncharacterised splicing events that restore the open reading frame. There are five out-of-frame AUGs between the primary AUG and the next in-frame AUG at codon 94. However, none of them are in a good sequence context in comparison with the optimal Kozak sequence, suggesting that they are unlikely to function as translation-initiating codons. The most likely scenario, therefore, is that the translation complex scans the mRNA until it finds the in-frame AUGs at codons 94 or 125.
A number of studies have reported ATM mutation carriers to have a 2 -7-fold increased risk of breast cancer (Swift et al, 1991; Easton, 1994; Athma et al, 1996; Stankovic et al, 1998; Inskip et al, 1999; Janin et al, 1999; Geoffroy-Perez et al, 2001; Olsen et al, 2001; Bernstein et al, 2003; Thompson et al, 2005a, b; Reiman et al, 2011) , with increased risk presumably associated with loss of heterozygosity, the sporadic loss of the normal ATM allele, resulting in either total loss of or a large reduction in functional ATM protein. Interestingly, this is the fourth time that neurologically milder A-T has been diagnosed following radiotherapy for breast cancer (Stankovic et al, 1998; Fang et al, 2010; Mandigers et al, 2011) . Stankovic et al (1998) reported a woman who experienced a severe reaction of the breast and skin tissues after receiving adjuvant radiotherapy following resection of her breast cancer. This woman and two siblings, including a sister who also developed breast cancer, were homozygous for the ATM mutation c.7271T4G (p.Val2424Gly). The mutation was also identified in a second A-T family where breast cancer occurred in carriers of the mutation. The authors computed a relative risk of 12.7 associated with carrying this ATM mutation, compared with a relative risk of 74.1 in homozygotes, of developing breast cancer (Stankovic et al, 1998) .
Two other cases have been described. In the first case, a 50-yearold breast cancer patient had a severe late adverse normal tissue reaction to radiotherapy (Fang et al, 2010) . Nucleotide sequence analysis identified two nonallelic mutations in novel premature termination mutation (c.1918A4T (Lys640Stop) ) and a (c.1066-6T4G (IVS10-6T-G)), which has previously been reported in A-T patients (Austen et al, 2008) . Although not described as an A-T patient, this must be a strong possibility. In the second case, a 42-year-old breast cancer patient showed extreme radiosensitivity in response to adjuvant radiotherapy following mastectomy (Mandigers et al, 2011) . Only one ATM mutation (c.8147T4C (p.Val2716Ala)), which also has some ATM kinase activity (Verhagen et al, 2009) , was identified and the patient subsequently diagnosed with A-T.
It is not known whether the ATM mutations in patient A-T213 were the cause of her breast cancer, although her relatively young age and the absence of mutations in her BRCA1 and BRCA2 genes would be consistent with this. With regard to potential mechanism involving ATM, the presence of two mutant ATM proteins, (p.Gly2891Asp and the c.1A4G derived protein) raises the possibility of a dominant-negative effect of the inactive protein on the active one. However, there is no evidence of a significant effect of the inactive c.1A4G derived protein in reducing the activity of the more abundant active p.Gly2891Asp protein, using the levels of phosphorylation of ATM target proteins as a measure of this potential effect. Although the mechanism of breast cancer development is not known, it is possible that the overall level of ATM kinase activity is below the threshold for tumour protection and, indeed, any small dominant-negative effect of the inactive protein could contribute to this. An alternative mechanism for the development of breast cancer could be gain of function associated with a mutant ATM protein; this could also apply to both the p.Val2424Gly and the p.Val2716Ala ATM mutations.
The relationship between the clinical and cellular radiosensitivity in patient A-T213 is of some importance because despite not having the more extreme cellular radiosensitivity of a 'classical A-T patient', she clearly showed a severe clinical radiosensitivity. There are insufficient data to relate the severity of the clinical end point to that of the cellular end point, in terms of radiosensitivity. It is not possible to determine whether the residual activity of ATM protein expressed in her cells afforded her some degree of protection against the worst possible effect of the irradiation dose or, more generally, what is the threshold of cellular radiosensitivity that will result in a clinically severe reaction to IR.
